Hyftor® (sirolimus gel)

About Plusultra Pharma

Plusultra Pharma is a commercial-stage, European subsidiary of Japan's Nobelpharma Group, operating with a mission-driven focus on neglected therapies for rare diseases. The company has successfully launched Hyftor® gel, an orphan drug for which it has secured German reimbursement and established marketing partnerships for expansion into France and Italy. As a private entity leveraging its parent group's R&D and commercial infrastructure, Plusultra aims to build a sustainable pipeline of specialized, small-molecule pharmaceuticals targeting high-unmet-need conditions.

Therapeutic Areas